In conclusion, our study shows that the KIT-blocking TKI imatinib produces a profound decrease in MC in mice as well as a decrease in MC in patients with Ph+ CML. The gene discussed is KIT; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.